{
  "drug_name": "Clopidogrel",
  "url": "https://wikem.org/wiki/Clopidogrel",
  "scraped_at": "2026-01-10T03:09:53.974014",
  "sections": {
    "General": {
      "text": "Type:\nAntiplatelet\nDosage Forms: 75mg, 300mg PO\nCommon Trade Names: Plavix",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "Antiplatelet",
          "url": "https://wikem.org/wiki/Antiplatelet"
        }
      ]
    },
    "Adult_Dosing": {
      "text": "",
      "subsections": {
        "Age_and_Indication_Related_Dosages[1][2][3]": {
          "text": "",
          "tables": [
            [
              {
                "": "STEMIwith fibrinolysis",
                "Trial": "CLARITY",
                "Age < 75": "300 mg",
                "Age > 75": "75 mg"
              },
              {
                "": "STEMIwith PCI",
                "Trial": "OASIS-7",
                "Age < 75": "600 mg",
                "Age > 75": "300 mg"
              },
              {
                "": "NSTEMI/UAwith ischemic EKG changes",
                "Trial": "CURE",
                "Age < 75": "300 mg",
                "Age > 75": "75 mg"
              }
            ]
          ]
        },
        "Post-Acute_coronary_syndrome": {
          "text": "Unstable angina\n,\nNSTEMI\n: Start 300mg PO x 1, then 75mg PO QD\nSTEMI\n: 75mg/day PO (in combination with\naspirin\n162-325mg/day\nRecent MI,\nStroke\n, or\nPeripheral Arterial Disease\n: 75mg PO QD",
          "tables": []
        },
        "Thrombotic_event_prevention": {
          "text": "75mg PO QD",
          "tables": []
        }
      },
      "tables": [],
      "links": [
        {
          "text": "Unstable angina",
          "url": "https://wikem.org/wiki/Unstable_angina"
        },
        {
          "text": "NSTEMI",
          "url": "https://wikem.org/wiki/NSTEMI"
        },
        {
          "text": "STEMI",
          "url": "https://wikem.org/wiki/STEMI"
        },
        {
          "text": "aspirin",
          "url": "https://wikem.org/wiki/Aspirin"
        },
        {
          "text": "Stroke",
          "url": "https://wikem.org/wiki/Stroke"
        }
      ]
    },
    "Pediatric_Dosing": {
      "text": "Not Recommended",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Special_Populations": {
      "text": "Pregnancy Rating\n: B\nLactation: Safety Unknown\nRenal Dosing\nAdult: not defined\nPediatric\nHepatic Dosing\nAdult: no adjustment\nPediatric",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "Pregnancy Rating",
          "url": "https://wikem.org/wiki/Drug_Ratings_in_Pregnancy"
        }
      ]
    },
    "Contraindications": {
      "text": "Allergy to class/drug\nactive bleeding\ncaution if trauma\ncaution if elective surgery within 5 days\ncaution if GI disorder\ncaution if ocular disease\ncaution if poor or intermediate CYP2C19 metabolizer\ncaution if renal impairment, mod-severe",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Adverse_Reactions": {
      "text": "",
      "subsections": {
        "Serious": {
          "text": "bleeding, severe,\nhemorrhage\nTTP\nagranulocytosis\nhypersensitivity reaction\nanaphylactoid reaction\nStevens-Johnson syndrome\ntoxic epidermal necrolysis\nerythema multiforme\ndrug rash with eosinophilia and systemic symptoms\nEosinophilic pneumonia",
          "tables": []
        },
        "Common": {
          "text": "bleeding\npruritus",
          "tables": []
        }
      },
      "tables": [],
      "links": [
        {
          "text": "TTP",
          "url": "https://wikem.org/wiki/TTP"
        },
        {
          "text": "Stevens-Johnson syndrome",
          "url": "https://wikem.org/wiki/Stevens-Johnson_syndrome"
        },
        {
          "text": "toxic epidermal necrolysis",
          "url": "https://wikem.org/wiki/Toxic_epidermal_necrolysis"
        },
        {
          "text": "erythema multiforme",
          "url": "https://wikem.org/wiki/Erythema_multiforme"
        }
      ]
    },
    "Pharmacology": {
      "text": "Half-life: 8h\nMetabolism: liver, CYP450: 1A2, 2C9, 2C19 (primary), 3A4 substrate\nExcretion: urine 50%, feces 46%\nMechanism of Action: irreversibly binds to P2Y12 adenosine diphosphate receptors, reducing platelet activation and aggregation",
      "subsections": {},
      "tables": [],
      "links": []
    }
  }
}